Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at up to $7.8 billion.
In this article
Eli Lilly
said on Tuesday it would buy Centessa Pharmaceuticals
in a deal valued at up to $7.8 billion as the U.S. drugmaker looks to diversify beyond its metabolic portfolio and expand into treatments for sleep disorders.
UK-based Centessa is developing treatments for excessive daytime sleepiness and other neurological conditions. Its lead therapy is currently in mid-stage studies for narcolepsy or excessive daytime sleepiness.
Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for…
A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones, The…
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered…
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo…
Pharma. Il colosso Usa punta, oltre alle cure per dimagrire, su settori quali oncologia ed immunologia. Il nodo dell’incognita…
